^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PVX2

    i
    Other names: PVX2, TA-CIN Vaccine
    Associations

    News

    Trials
    Company:
    PapiVax
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    6ms
    Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date
    |
    PVX2
    6ms
    PVX-2: Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL (clinicaltrials.gov)
    P2, N=16, Terminated, PapiVax Biotech, Inc. | N=134 --> 16 | Recruiting --> Terminated; Slow recruitment/funding
    Enrollment change • Trial termination • Cytology
    |
    PVX2
    over1year
    Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PVX2